Is the GlaxoSmithKline share price a bargain or should I buy this high-yielding small-cap?

Does this small-cap share’s recovery potential outshine the forward prospects of GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of Vertu Motors (LSE: VTU) continued its slide today on the release of interim results. The automotive retailer has a network of 125 sales and aftersales outlets across the UK and the shares are down around 22% since the end of August.

Today’s figures show that revenue increased by around 7.6% compared to the equivalent period last year, but adjusted earnings per share fell by 8%. There’s nothing the stock market hates more than falling earnings, so I think we’ve found the reason for the weakness in the share price. The directors held the interim dividend firm at last year’s level.

Big acquisition

In July, towards the end of the period, the company spent almost £22m acquiring Hughes Group Holdings Limited, which came with a “significant Mercedes-Benz presence in the M4/M40 corridor.” I think that’s a bold move with so many economic uncertainties on the horizon. The balance sheet was weakened and the firm reported net debt on 31 August of £8.7m, which compares to a net cash position of £20.8m the year before.

Car dealership businesses are notoriously cyclical and when trading conditions have been good and profitable, I reckon it makes sense for them to build up their cash reserves so that they can survive the next downturn in the economy. Indeed, the current trading and outlook statement is a little murky and highlights several risks.

The company said that supply-side issues in the new car market led to declining volumes with September registrations being the lowest since 2011.” September trading was affected by Worldwide Harmonised Light Vehicle Test Procedure (WLTP) emissions regulations across the European Union. Meanwhile, car margins are under pressure because the depressed level of Sterling is affecting manufacturers’ profitability. The firm reckons some supply issues are “likely to continue into early 2019.”

Give me steady demand

Demand for cars is holding up for the time being but the directors admit that political uncertainty in the UK could lead to consumer uncertainty and volatility for the rest of the firm’s trading year. The company goes on to list a number of positives, but the stock market looks wary of the stock to me. And I share the market’s concerns. Despite the firm’s high-looking dividend yield and substantial asset backing from the property it owns, I think the shares are vulnerable to downside shocks, so I’d rather invest in a less cyclical firm such as pharmaceutical outfit GlaxoSmithKline (LSE: GSK).

One of the main attractions of the firm to me is that its pharmaceutical business resides at the opposite end of the defensive/cyclical scale from Vertu Motors. Unlike big-ticket purchases such as cars, people keep buying their medicines whatever the economic climate and such reliable repeat-purchasing tends to lead to consistent cash inflows.

On top of that, GlaxoSmithKline is paying a bigger dividend than Vertu Motors anyway. The recent share price close to 1,487p throws up a tempting forward yield of 5.4% for 2019. I think that GlaxoSmithKline is recovering well from a period of declining earnings as previously best-selling drugs lost their patent protection. I’d rather take my chances with the firm’s forward prospects than with the uncertain outlook of a cyclical firm such as Vertu Motors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Vertu Motors. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The FTSE 100 reaches an all-time high! Here are 2 of its best stocks to consider buying

With the FTSE 100 soaring in 2024, this Fool thinks investors should consider buying these two stocks. Here he breaks…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Here’s why I see cheap UK shares soaring in the years ahead

UK shares look undervalued and this Fool plans to take advantage of it. Here he details one stock he's keen…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Dividend Shares

Is Legal & General the best stock to buy in the FTSE right now?

UK investors have been piling into Legal & General in recent weeks. But are there better FTSE shares to buy…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With no savings at 40, I’d buy and hold these 2 FTSE 250 stocks to retirement

Jon Smith outlines two FTSE 250 stocks that he believes offer long-term value for an investors that's looking to build…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,000 in savings? Here’s how I’d try to turn that into £7,864 every year in passive income

Investing a relatively small amount in high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Is Aviva’s share price a bargain now it’s trading well below £5?

Aviva’s share price has slumped to well below £5, but even before that it looked a bargain to me, with…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Rolls-Royce shares: tapped out at £4 or poised to climb further?

Rolls-Royce shares are finally showing signs of faltering after months of gains. Can they still climb further or is a…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Up 30%, this FTSE 100 stock has been my best buy in 2024

I’m considering the prospects of my best-performing FTSE 100 stock this year. Can this major UK bank continue to make…

Read more »